IPP Bureau

Briefs: Dr. Reddy's Laboratories, Relonchem,  Shilpa Pharma Lifesciences and Shanmuga Hospital
Briefs: Dr. Reddy's Laboratories, Relonchem, Shilpa Pharma Lifesciences and Shanmuga Hospital

By IPP Bureau - May 18, 2025

Shilpa Pharma Lifesciences, Unit-1, received EIR from USFDA

Sun Pharma gets FDA approval for new device to treat skin disease
Sun Pharma gets FDA approval for new device to treat skin disease

By IPP Bureau - May 18, 2025

Punita Lal Joins Lupin Board as Additional Director
Punita Lal Joins Lupin Board as Additional Director

By IPP Bureau - May 18, 2025

She has held senior positions at Coca-Cola in China and PepsiCo in India

Lupin receives USFDA approval for Rivaroxaban Tablets
Lupin receives USFDA approval for Rivaroxaban Tablets

By IPP Bureau - May 18, 2025

Alembic Pharmaceuticals receives USFDA final approval for Rivaroxaban Tablets USP
Alembic Pharmaceuticals receives USFDA final approval for Rivaroxaban Tablets USP

By IPP Bureau - May 18, 2025

Abbott India posts Q4 FY25 net profit at Rs. 367.04 Cr
Abbott India posts Q4 FY25 net profit at Rs. 367.04 Cr

By IPP Bureau - May 18, 2025

The company has posted net profit of Rs. 1,414.44 crores for the Financial Year ended March 31, 2025

Wanbury posts Q4 FY25 consolidated PAT at Rs. 20.25 Cr
Wanbury posts Q4 FY25 consolidated PAT at Rs. 20.25 Cr

By IPP Bureau - May 18, 2025

The company has posted net profit of Rs. 30.53 crores for the Financial Year ended March 31, 2025

Solara Active Pharma Sciences posts Q4 FY25 consolidated loss at Rs. 2.10 Cr
Solara Active Pharma Sciences posts Q4 FY25 consolidated loss at Rs. 2.10 Cr

By IPP Bureau - May 18, 2025

The company has posted net profit of Rs. 0.54 crores for the Financial Year ended March 31, 2025

Neuland Laboratories posts Q4 FY25 consolidated PAT at Rs. 27.80 Cr
Neuland Laboratories posts Q4 FY25 consolidated PAT at Rs. 27.80 Cr

By IPP Bureau - May 18, 2025

The company has posted net profit of Rs. 260.10 crores for the Financial Year ended March 31, 2025

IOL Chemicals and Pharmaceuticals posts Q4 FY25 PAT at Rs. 31.42 Cr
IOL Chemicals and Pharmaceuticals posts Q4 FY25 PAT at Rs. 31.42 Cr

By IPP Bureau - May 17, 2025

IOL Chemicals and Pharmaceuticals has posted net profit of Rs.101.07 crores for the Financial Year ended March 31, 2025

Jubilant Pharmova posts Q4 FY25 consolidated PAT at Rs. 153.6 Cr
Jubilant Pharmova posts Q4 FY25 consolidated PAT at Rs. 153.6 Cr

By IPP Bureau - May 17, 2025

Jubilant Pharmova has posted net profit of Rs. 839.4 crores for the Financial Year ended March 31, 2025

JB Pharma records revenue growth of 10% to Rs. 949 crore in Q4 FY25
JB Pharma records revenue growth of 10% to Rs. 949 crore in Q4 FY25

By IPP Bureau - May 16, 2025

Net Profit increased by 15% to Rs. 146 crores in Q4 FY25 and 19% to Rs. 660 crores in FY25

Shelter Pharma launches three new products
Shelter Pharma launches three new products

By IPP Bureau - May 16, 2025

Shelter Pharma Limited is set to capitalize on the growing demand for natural health products in India

Remedium Lifecare secures Rs. 182.7 crore export deal
Remedium Lifecare secures Rs. 182.7 crore export deal

By IPP Bureau - May 16, 2025

The CDMO upgrade represents a transformational step for Remedium Lifecare

Lupin posts consolidated Q4 FY25 PAT at Rs. 772.52 Cr
Lupin posts consolidated Q4 FY25 PAT at Rs. 772.52 Cr

By IPP Bureau - May 16, 2025

Latest Stories

Interviews

Packaging